RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults.

Inclusion Criteria: * signed and dated an informed consent form and HIPAA. * Subjects without symptomatic cardiopulmonary and/or metabolic disease. * Body mass index (BMI) ≥ 18.5 and ≤ 34.9. * Negative human immunodeficiency virus antibody test (anti-HIV), HBsAG and HCV virus. * Electrocardiogram (ECG) without clinically significant acute findings. * WOCBP must have a negative serum pregnancy test at screening and a negative urine pregnancy test prior to each vaccination. Exclusion Criteria: * History of nasal or sinus surgery within six months prior to screening or planned nasal or sinus surgery during the trial * Active or recent history (within 6 months prior to screening) of chronic sinusitis, nasopharyngeal abnormalities and/or symptoms such as polyps or deviated septum * pregnant or breast-feeding women. * History or current clinical manifestation of any serious medical condition. * History of or active autoimmune disease. * Known or suspected impairment of immunologic functions including, but not limited to chronic inflammatory bowel disorders, diabetes mellitus type I. * Knowledge/history of allergic disease or reactions likely to be exacerbated by any component of the vaccine. * History of anaphylaxis or severe allergic reaction to any vaccine. * Chronic systemic administration defined as more than 14 days of \> 5 mg prednisone per day